Literature DB >> 31938029

Tumor suppressor role of genes involved in circadian clock control.

Reham Hassan1.   

Abstract

Entities:  

Year:  2019        PMID: 31938029      PMCID: PMC6953534          DOI: 10.17179/excli2019-2072

Source DB:  PubMed          Journal:  EXCLI J        ISSN: 1611-2156            Impact factor:   4.068


× No keyword cloud information.



In recent years evidence has accumulated that genes involved in circadian clock control play a role as tumor suppressors. Strong evidence has been presented by Broadberry and colleagues who published an article about disrupted circadian clocks in breast cancer (Broadberry et al., 2018[1]). The authors studied primary mammary epithelial cells from normal breast tissue and epithelial cells from breast carcinomas of the same patients. They transduced the cells with the luciferase clock reporter PER2:Luc, which is known to show a robust ~24 h rhythm in normal epithelial cells (Yang et al., 2017[20]). The normal epithelial breast cells showed the expected cycling. However, epithelial cells from the cancer tissue of the same individuals showed a disrupted rhythm with a much lower amplitude (Broadberry et al., 2018[1]). This study confirms previous studies presenting evidence for a tumor suppressor role of the circadian clock (Gery and Koeffler, 2010[7]; Grundy et al., 2013[9]; Fu and Lee, 2003[6]; Mormont and Lévi, 1997[15]; Filipski et al., 2002[5]). Loss of clock genes has been shown to be associated with worse prognosis in breast cancer (Cadenas et al., 2014[3]). Coordinated co-expression of clock genes (e.g. PER2-PER3 and CRY2-PER3) is maintained in estrogen receptor positive and HER2 negative carcinomas but is compromised in more aggressive tumors (Cadenas et al., 2014[3]). Genes relevant for progression of breast carcinomas have been shown to be associated with proliferation (Siggelkow et al., 2012[18]), the cellular and humoral immune system (Schmidt et al., 2008[16], 2012[17]; Heimes et al., 2017[10][11]; Lohr et al., 2013[13]; Godoy et al., 2014[8]), anti-oxidative and anti-apoptotic factors (Hellwig et al., 2016[12]; Cadenas et al., 2010[2]) and altered metabolism (Cadenas et al., 2019[4]; Marchan et al., 2017[14]; Stewart et al., 2012[19]). Although the loss of circadian clock gene expression and its association with tumor prognosis has clearly been shown, the mechanisms of their tumor suppressive effect still need to be elucidated.
  20 in total

Review 1.  Circadian rhythms and cancer.

Authors:  Sigal Gery; H Philip Koeffler
Journal:  Cell Cycle       Date:  2010-03-15       Impact factor: 4.534

2.  Host circadian clock as a control point in tumor progression.

Authors:  Elisabeth Filipski; Verdun M King; XiaoMei Li; Teresa G Granda; Marie-Christine Mormont; XuHui Liu; Bruno Claustrat; Michael H Hastings; Francis Lévi
Journal:  J Natl Cancer Inst       Date:  2002-05-01       Impact factor: 13.506

Review 3.  Circadian-system alterations during cancer processes: a review.

Authors:  M C Mormont; F Lévi
Journal:  Int J Cancer       Date:  1997-01-17       Impact factor: 7.396

4.  A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors.

Authors:  Marcus Schmidt; Birte Hellwig; Seddik Hammad; Amnah Othman; Miriam Lohr; Zonglin Chen; Daniel Boehm; Susanne Gebhard; Ilka Petry; Antje Lebrecht; Cristina Cadenas; Rosemarie Marchan; Joanna D Stewart; Christine Solbach; Lars Holmberg; Karolina Edlund; Hanna Göransson Kultima; Achim Rody; Anders Berglund; Mats Lambe; Anders Isaksson; Johan Botling; Thomas Karn; Volkmar Müller; Aslihan Gerhold-Ay; Christina Cotarelo; Martin Sebastian; Ralf Kronenwett; Hans Bojar; Hans-Anton Lehr; Ugur Sahin; Heinz Koelbl; Mathias Gehrmann; Patrick Micke; Jörg Rahnenführer; Jan G Hengstler
Journal:  Clin Cancer Res       Date:  2012-02-20       Impact factor: 12.531

Review 5.  The circadian clock: pacemaker and tumour suppressor.

Authors:  Loning Fu; Cheng Chi Lee
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

6.  Shift work, circadian gene variants and risk of breast cancer.

Authors:  Anne Grundy; Johanna M Schuetz; Agnes S Lai; Rozmin Janoo-Gilani; Stephen Leach; Igor Burstyn; Harriet Richardson; Angela Brooks-Wilson; John J Spinelli; Kristan J Aronson
Journal:  Cancer Epidemiol       Date:  2013-05-28       Impact factor: 2.984

7.  Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis.

Authors:  Joanna D Stewart; Rosemarie Marchan; Michaela S Lesjak; Joerg Lambert; Roland Hergenroeder; James K Ellis; Chung-Ho Lau; Hector C Keun; Gerd Schmitz; Juergen Schiller; Mandy Eibisch; Christian Hedberg; Herbert Waldmann; Ekkehart Lausch; Berno Tanner; Jalid Sehouli; Jens Sagemueller; Hagen Staude; Eric Steiner; Jan G Hengstler
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-08       Impact factor: 11.205

8.  Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy.

Authors:  Birte Hellwig; Katrin Madjar; Karolina Edlund; Rosemarie Marchan; Cristina Cadenas; Anne-Sophie Heimes; Katrin Almstedt; Antje Lebrecht; Isabel Sicking; Marco J Battista; Patrick Micke; Marcus Schmidt; Jan G Hengstler; Jörg Rahnenführer
Journal:  PLoS One       Date:  2016-12-07       Impact factor: 3.240

9.  LIPG-promoted lipid storage mediates adaptation to oxidative stress in breast cancer.

Authors:  Cristina Cadenas; Sonja Vosbeck; Karolina Edlund; Katharina Grgas; Katrin Madjar; Birte Hellwig; Alshaimaa Adawy; Annika Glotzbach; Joanna D Stewart; Michaela S Lesjak; Dennis Franckenstein; Maren Claus; Heiko Hayen; Alexander Schriewer; Kathrin Gianmoena; Sonja Thaler; Marcus Schmidt; Patrick Micke; Fredrik Pontén; Adil Mardinoglu; Cheng Zhang; Heiko U Käfferlein; Carsten Watzl; Saša Frank; Jörg Rahnenführer; Rosemarie Marchan; Jan G Hengstler
Journal:  Int J Cancer       Date:  2019-02-07       Impact factor: 7.396

10.  Loss of circadian clock gene expression is associated with tumor progression in breast cancer.

Authors:  Cristina Cadenas; Leonie van de Sandt; Karolina Edlund; Miriam Lohr; Birte Hellwig; Rosemarie Marchan; Marcus Schmidt; Jörg Rahnenführer; Henrik Oster; Jan G Hengstler
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.